tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'Clinical Trials'

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

PharmaCyte Biotech’s Release Testing Last Critical Event Before Submission of Investigational New Drug Application

Written by Ι Stock Market Media — November 12, 2019

PharmaCyte Biotech (OTCQB: PMCB) has reduced a long list of FDA-required items to just one last important component—release testing—before it can submit an Investigational New Drug application (IND) to the U.S. FDA.  PharmaCyte’s IND application will request permission from the FDA to conduct a Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC).  With the FDA’s approval to begin a clinical trial, PharmaCyte’s opportunities for funding improve dramatically.

PharmaCyte has already ...

Read More →
0

PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

PharmaCyte Biotech to Change Future of Treating Diseases with Validation of Encapsulation Technology in Pancreatic Cancer Trial

Written by Ι Stock Market Media — October 28, 2019

PharmaCyte Biotech (OTCQB: PMCB) has a technology that could very well change the way a host of hard-to-treat diseases are treated for the foreseeable future.  The company is closer than ever to its upcoming Phase 2b clinical trial in locally advanced, inoperable pancreatic cancer (LAPC) that could give patients a new lease on life by shrinking their tumors enough so that the tumors can be removed surgically.  It is an outcome that would ...

Read More →
0

PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

PharmaCyte Biotech Nearing Major Milestone—An Open IND with the FDA

Written by Ι Stock Market Media — February 4, 2019

Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...

Read More →
0

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Plandaí Biotechnology’s Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes

Written by Ι Stock Market Media — May 18, 2017

Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable green tea extract, Phytofare® Catechin Complex, to regulate blood glucose levels in type 2 diabetics. If the positive data that was recently published in the Journal of Human Nutrition and Dietetics is any indicator, Plandaí should expect to receive its own positive data. The two studies could complement one another, and Plandaí’s ...

Read More →
0

New Video Documents Plandaí Biotechnology’s $20 Million Operation at Senteeko Tea Estate

New Video Documents Plandaí Biotechnology’s $20 Million Operation at Senteeko Tea Estate

Written by Ι Stock Market Media Group Staff — April 14, 2015

NEW YORK, NY – Plandaí Biotechnology (OTCQB: PLPL) and its operations at the Senteeko tea estate in South Africa are the subject of a newly released video. Stock Market Media Group, a content development investment relations firm, spent a week in South Africa with a camera crew from Bay Colony Media documenting the company’s story, and announced today that the documentary is now available.  

Click Here to View ...

Read More →
0

Nuvilex, Inc. Moves Closer to “Bio-Artificial Pancreas” Diabetes Treatment with License for Insulin-Producing Cells

Written by Ι Stock Market Media Group Staff — October 21, 2014

Nuvilex, Inc. (OTCQB: NVLX) has carefully mapped out its plan to develop a diabetes treatment using the Cell-in-a-Box® platform technology.  It started in November 2013 when the company acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes.  This acquisition gave Nuvilex a proven delivery system with which it could firmly plant its flag in the race for a diabetes treatment.

Now, almost ...

Read More →
0
Page 1 of 6 12345...»
ContactUs.com